These effects are typically mild to moderate, dose-dependent, and tend to diminish with continued use and proper dose escalation
Based on head-to-head clinical studies, Mounjaro (tirzepatide) has been shown to be more effective, or "stronger," for both weight loss and lowering blood sugar compared to Ozempic (semaglutide)
Symptoms such as mild weight gain, mild fatigue, mild constipation, and even some mild hair fall
Research has documented MT-1s anti-inflammatory effects across skin cell models and systemic inflammatory models , characterising NF-B suppression, reduced TNF-alpha and IL-6 production, neutrophil activation inhibition, and anti-inflammatory effects in ischaemia-reperfusion and colitis models through MC1R-cAMP-mediated mechanisms